Fleckenstein Jochen, Eschler Andrea, Kremp Katharina, Kremp Stephanie, Rübe Christian
Department of Radiotherapy and Radiation Oncology, Saarland University Medical School, 66421, Homburg, Germany.
Department of Diagnostic and Interventional Radiology, Saarland University Medical School, Homburg, Germany.
Radiat Oncol. 2015 Aug 21;10:178. doi: 10.1186/s13014-015-0485-6.
The advent of IMRT and image-guided radiotherapy (IGRT) in combination with involved-field radiotherapy (IF-RT) in inoperable non-small-cell lung cancer results in a decreased incidental dose deposition in elective nodal stations. While incidental nodal irradiation is considered a relevant by-product of 3D-CRT to control microscopic disease this planning study analyzed the impact of IMRT on dosimetric parameters and tumor control probabilities (TCP) in elective nodal stations in direct comparison with 3D-CRT.
The retrospective planning study was performed on 41 patients with NSCLC (stages II-III). The CTV was defined as the primary tumor (GTV + 3 mm) and all FDG-PET-positive lymph node stations. As to the PTV (CTV + 7 mm), both an IMRT plan and a 3D-CRT plan were established. Plans were escalated until the pre-defined dose-constraints of normal tissues (spinal cord, lung, esophagus and heart) were reached. Additionally, IMRT plans were normalized to the total dose of the corresponding 3D-CRT. For two groups of out-of-field mediastinal node stations (all lymph node stations not included in the CTV (LNall_el) and those directly adjacent to the CTV (LNadj_el)) the equivalent uniform dose (EUD) and the TCP (for microscopic disease a D50 of 36.5 Gy was assumed) for the treatment with IMRT vs 3D-CRT were calculated.
In comparison, a significantly higher total dose for the PTV could be achieved with the IMRT planning as opposed to conventional 3D-CRT planning (74.3 Gy vs 70.1 Gy; p = 0.03). In identical total reference doses, the EUD of LNadj_el is significantly lower with IMRT than with 3D-CRT (40.4 Gy vs. 44.2 Gy. P = 0.05) and a significant reduction of TCP with IMRT vs 3D-CRT was demonstrated for LNall_el and LNadj_el (12.6% vs. 14.8%; and 23.6% vs 27.3%, respectively).
In comparison with 3D-CRT, IMRT comes along with a decreased EUD in out-of-field lymph node stations. This translates into a statistically significant decrease in TCP-values. Yet, the combination of IF-RT and IMRT leads to a significantly better sparing of normal tissues and higher total doses whereas the potential therapeutic drawback of decreased incidental irradiation of elective lymph nodes is moderate.
调强放疗(IMRT)和图像引导放疗(IGRT)与累及野放疗(IF-RT)相结合应用于不可切除的非小细胞肺癌,使得选择性淋巴结区域的附带剂量沉积减少。虽然附带淋巴结照射被认为是三维适形放疗(3D-CRT)控制微小病灶的一个相关副产物,但本计划研究通过与3D-CRT直接比较,分析了IMRT对选择性淋巴结区域剂量学参数和肿瘤控制概率(TCP)的影响。
对41例非小细胞肺癌(II-III期)患者进行回顾性计划研究。临床靶区(CTV)定义为原发肿瘤(大体肿瘤体积+3mm)和所有FDG-PET阳性淋巴结区域。对于计划靶区(CTV+7mm),分别制定IMRT计划和3D-CRT计划。计划剂量逐步增加,直至达到正常组织(脊髓、肺、食管和心脏)的预定义剂量限制。此外,IMRT计划归一化为相应3D-CRT的总剂量。对于两组野外纵隔淋巴结区域(所有未包含在CTV中的淋巴结区域(LNall_el)和那些直接毗邻CTV的区域(LNadj_el)),计算IMRT与3D-CRT治疗时的等效均匀剂量(EUD)和TCP(对于微小病灶,假定D50为36.5Gy)。
相比之下,与传统的3D-CRT计划相比,IMRT计划能够使计划靶区获得显著更高的总剂量(74.3Gy对70.1Gy;p=0.03)。在相同的总参考剂量下,IMRT时LNadj_el的EUD显著低于3D-CRT(40.4Gy对44.2Gy,P=0.05),并且对于LNall_el和LNadj_el,显示IMRT相对于3D-CRT时TCP显著降低(分别为12.6%对14.8%;23.6%对27.3%)。
与3D-CRT相比,IMRT使野外淋巴结区域的EUD降低。这转化为TCP值在统计学上显著降低。然而,IF-RT与IMRT相结合可显著更好地保护正常组织并提高总剂量,而选择性淋巴结附带照射减少的潜在治疗缺陷是适度的。